Category: Imaging & mpMRI
Dr. Peter Pinto is one of the most respected urologic researchers in America. He is the Head of the Prostate Cancer Section of the Urologic Oncology Branch of the Center for Cancer Research (National Cancer Institute/National Institutes of Health). That’s a very long formal title for a man who is humble, personable and good-natured. His keep reading
When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading
When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading
It is always gratifying for a doctor when something he or she wholeheartedly believes in gets affirmed by published research. For me, this is the case with a new Italian study, “The Roles of Multiparametric MRI, PCA3, and PHI: Which Is The Best Predictor of Prostate Cancer After a Negative Biopsy?”[i] The authors recognize the keep reading
I’m excited to announce news about a new way to quantify the effects of focal laser ablation (FLA) in a way that may allow us to predict long term treatment success. I was a member of a research team out of Case Western Reserve University that developed an innovative way to use MRI before, during keep reading
A prominent urologist wrote an articulate article on how the U.S. Preventive Services Task Force made a recommendation against broad PSA screening based on an oversimplification of a complex issue. He made an eloquent declaration on several ways in which urologists are “embracing strategies to preserve, or even further decrease, prostate cancer mortality while minimizing keep reading
It’s always reassuring to receive affirmation, especially when offering a leading edge medical program to prostate cancer patients. Such was the case for us at the Sperling Prostate Center with the December, 2015 publication of a UCLA Medical Center study on the value-added of multiparametric MRI during Active Surveillance (AS). The authoritative Journal of Urology keep reading
Nanoparticles are very, very small objects that have the properties of the larger unit from which they are derived. Nanoparticles sound like something discovered by physicists, but in fact they have been used by artisans for over 1,000 years to add metallic luster to the surface of pottery and other artistic creations. Today, medical science keep reading
“Everyone is keeping up with the Joneses, and there are more Joneses than ever.” This statement from art critic Jerry Saltz refers to the buying habits of a public hungry for trendy art. However, it could as easily apply to MRI technology, where the strength of the magnet—measured in units called Tesla, or T—makes all keep reading
Back in May, I posted an article on our website about Haralick texture analysis as an amplification of prostate cancer features on multiparametric MRI. On July 28, a journal article on which I based the piece I posted was picked up by a medical news service, so I thought it was worth bringing attention to keep reading
